Shichun Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shichun Tu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Sultan
Neurodegenerative Disease Center, Scintillon Institute, San Diego, USA
1 shared publication Alejandro Amador-Arjona
Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA
1 shared publicationAlexey V. Terskikh
Neuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA
1 shared publicationAmanda J. Roberts
Department of Neuroscience and Mouse Behavioral Assessment Core, The Scripps Research Institute, La Jolla, CA, 92037, USA
1 shared publicationDandan Zhu
Zhengzhou Shenyou Biotechnology, Zhengzhou, Henan 450000, P.R. China
1 shared publicationDaniel H. Geschwind
Center for Autism Research and Treatment (CART), University of California, Los Angeles, CA, 90095, USA
1 shared publication
Latest Publications
- Open Access
- 11 March 2024
- Published by Spandidos Publications in Oncology Letters
- Vol. 27 (5) , 1-9
Multi‑omics approach to improve patient‑tailored therapy using immune checkpoint blockade and cytokine‑induced killer cell infusion in an elderly patient with lung cancer: A case report and literature review
The 5‑year survival rate of patients with advanced non‑small cell lung cancer (NSCLC) remains low, despite recent advances in targeted therapy and immunotherapy. Therefore, there is a need to identify alternative strategies to improve treatment outcomes. Modern diagnostics can significantly facilitate the selection of treatment plans to improve patient outcomes. In the present study, multi‑form diagnostic methodologies were adopted, including next‑generation sequencing‑based actionable gene sequencing, programmed death ligand 1 (PD‑L1) immunohistochemistry, a circulating tumor cell (CTC) assay, flow cytometric analysis of lymphocyte subsets and computed tomography, to improve disease management in an 86‑year‑old female patient with relapsed metastatic NSCLC. High expression of PD‑L1, elevated CTC tmutations, were observed. Based on these results, the patient was initially treated with the programmed death protein 1 blocking antibody sintilimab for two cycles, resulting in the stabilization of their condition, although the patient still exhibited severe pain and other symptoms, including fatigue, malaise, a loss of appetite and poor mental state. Informed by dynamic monitoring of the patient's response to treatment, the treatment plan was subsequently adjusted to a combination therapy with sintilimab and autologous cytokine‑induced killer cell infusion, which eventually led to improved outcomes in both the management of the cancer and quality of life. In conclusion, multi‑omics analysis may be used to establish patient‑tailored therapies to improve clinical outcomes in hard‑to‑treat elderly patients with metastatic NSCLC.
- 11 March 2024
- Published by Spandidos Publications in Oncology Letters
- Vol. 27 (5) , 1-9
Open AccessMulti‑omics approach to improve patient‑tailored therapy using immune checkpoint blockade and cytokine‑induced killer cell infusion in an elderly patient with lung cancer: A case report and literature review
The 5‑year survival rate of patients with advanced non‑small cell lung cancer (NSCLC) remains low, despite recent advances in targeted therapy and immunotherapy. Therefore, there is a need to identify alternative strategies to improve treatment outcomes. Modern diagnostics can significantly facilitate the selection of treatment plans to improve patient outcomes. In the present study, multi‑form diagnostic methodologies were adopted, including next‑generation sequencing‑based actionable gene sequencing, programmed death ligand 1 (PD‑L1) immunohistochemistry, a circulating tumor cell (CTC) assay, flow cytometric analysis of lymphocyte subsets and computed tomography, to improve disease management in an 86‑year‑old female patient with relapsed metastatic NSCLC. High expression of PD‑L1, elevated CTC tmutations, were observed. Based on these results, the patient was initially treated with the programmed death protein 1 blocking antibody sintilimab for two cycles, resulting in the stabilization of their condition, although the patient still exhibited severe pain and other symptoms, including fatigue, malaise, a loss of appetite and poor mental state. Informed by dynamic monitoring of the patient's response to treatment, the treatment plan was subsequently adjusted to a combination therapy with sintilimab and autologous cytokine‑induced killer cell infusion, which eventually led to improved outcomes in both the management of the cancer and quality of life. In conclusion, multi‑omics analysis may be used to establish patient‑tailored therapies to improve clinical outcomes in hard‑to‑treat elderly patients with metastatic NSCLC.
- 21 November 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 56 (1) , 7-17
Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review)
Although the majority of patients with follicular lymphoma (FL) harbor the t(14;18)(q32;q21) IGH/BCL2 gene rearrangement that leads to the overexpression of BCL2 protein, approximately 20% of FL cases lack t(14;18) (q32;q21). It is considered that BCL2 overexpression underscores the development of the majority of cases of FL and their transformation to more aggressive lymphoma [known as transformed FL (tFL)]. However, FL cases lacking the t(14;18) (q32;q21) translocation exhibit symptoms analogous to their t(14;18)-positive counterparts. An important goal of recent research on FL has been to clarify the distinctions between the two different forms of FL. Numerous studies have shed light onto the genetic and molecular features of t(14;18)-negative FL and the related clinical manifestations. In this review, we summarize the current knowledge of t(14;18)-negative FL occurring in the lymph nodes with an emphasis on the underlying molecular and clinical features. In addition, novel treatment directions are discussed.
- 21 November 2019
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 56 (1) , 7-17
Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review)
Although the majority of patients with follicular lymphoma (FL) harbor the t(14;18)(q32;q21) IGH/BCL2 gene rearrangement that leads to the overexpression of BCL2 protein, approximately 20% of FL cases lack t(14;18) (q32;q21). It is considered that BCL2 overexpression underscores the development of the majority of cases of FL and their transformation to more aggressive lymphoma [known as transformed FL (tFL)]. However, FL cases lacking the t(14;18) (q32;q21) translocation exhibit symptoms analogous to their t(14;18)-positive counterparts. An important goal of recent research on FL has been to clarify the distinctions between the two different forms of FL. Numerous studies have shed light onto the genetic and molecular features of t(14;18)-negative FL and the related clinical manifestations. In this review, we summarize the current knowledge of t(14;18)-negative FL occurring in the lymph nodes with an emphasis on the underlying molecular and clinical features. In addition, novel treatment directions are discussed.
- 1 April 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1869 (2) , 85-96
Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment
- 1 April 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1869 (2) , 85-96
Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment
- Open Access
- 14 November 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1-12
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
Transcription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy. However, molecular mechanisms underlyingMEF2Chaploinsufficiency syndrome remain poorly understood. Here we report thatMef2c+/−(Mef2c-het) mice exhibit behavioral deficits resembling those of human patients. Gene expression analyses on brains from these mice show changes in genes associated with neurogenesis, synapse formation, and neuronal cell death. Accordingly,Mef2c-het mice exhibit decreased neurogenesis, enhanced neuronal apoptosis, and an increased ratio of excitatory to inhibitory (E/I) neurotransmission. Importantly, neurobehavioral deficits, E/I imbalance, and histological damage are all ameliorated by treatment with NitroSynapsin, a new dual-action compound related to the FDA-approved drug memantine, representing an uncompetitive/fast off-rate antagonist of NMDA-type glutamate receptors. These results suggest thatMEF2Chaploinsufficiency leads to abnormal brain development, E/I imbalance, and neurobehavioral dysfunction, which may be mitigated by pharmacological intervention.
- 14 November 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 1-12
Open AccessNitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
Transcription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy. However, molecular mechanisms underlyingMEF2Chaploinsufficiency syndrome remain poorly understood. Here we report thatMef2c+/−(Mef2c-het) mice exhibit behavioral deficits resembling those of human patients. Gene expression analyses on brains from these mice show changes in genes associated with neurogenesis, synapse formation, and neuronal cell death. Accordingly,Mef2c-het mice exhibit decreased neurogenesis, enhanced neuronal apoptosis, and an increased ratio of excitatory to inhibitory (E/I) neurotransmission. Importantly, neurobehavioral deficits, E/I imbalance, and histological damage are all ameliorated by treatment with NitroSynapsin, a new dual-action compound related to the FDA-approved drug memantine, representing an uncompetitive/fast off-rate antagonist of NMDA-type glutamate receptors. These results suggest thatMEF2Chaploinsufficiency leads to abnormal brain development, E/I imbalance, and neurobehavioral dysfunction, which may be mitigated by pharmacological intervention.